The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:

• Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
• How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
• What needs to be done for GLP-1s to be covered
• Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
• Advice for investors and financiers who are considering entering the weight-loss medication market